At Exelixis, the past six months have been quite eventful. Following the implementation of our restructuring plan in the spring and the recent return of the XL184 program from Bristol-Myers Squibb, the Exelixis landscape has changed significantly since the start of the year.
At Exelixis, the past six months have been quite eventful. Following the implementation of our restructuring plan in the spring and the recent return of the XL184 program from Bristol-Myers Squibb, the Exelixis landscape has changed significantly since the start of the year.